|

The Impact of Magnesium on Exercise Tolerance, Quality of Life and Clinical Outcomes in Chronic Heart Failure Patients

RECRUITINGPhase 3Sponsored by Sheba Medical Center
Actively Recruiting
PhasePhase 3
SponsorSheba Medical Center
Started2019-08-25
Est. completion2026-01-01
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03840226

Summary

Magnesium supplementation could improve cardiac performance. Patients with chronic heart failure (CHF) are magnesium deficient and we hypothesized that 1 year supplementation of oral magnesium comparted to placebo will improve exercise duration time and quality of life.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* CHF patients NYHA II-IV \> 3 months
* Diuretic therapy \> 3 months
* Signed informed consent

Exclusion Criteria:

* chronic renal failure (serum creatinine \> 3 mg/dL)
* AMI/ACS\< 3 months from randomization
* Cardiac or other organ transplantation
* Uncontrolled hypo/hyperthyroidism
* Chronic diarrhea
* Life expectancy \< 1 year
* Known psychiatric disease which inhibits patient's enrollment to the study
* Inability to come for follow-up visits
* Any planned operation/invasive procedures in the near 6 months
* Uncontrolled cardiac arrhythmias
* Inability to perform 6 minute walk testing
* Any participation in another interventional clinical trial \< 1 month from randomization
* Any malignancy with life expectancy \< 1 year Any AV Block\> 2 degree without a pacemaker

Conditions3

Heart DiseaseHeart FailureMagnesium Deficiency

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.